Brain Damage, Glial Fibrillary Acidic Protein, Neuron Specific Enolase, Postoperative Cognitive Dysfunction
Conditions
Keywords
Liver transplantation, Neuronal damage, Brain, Biochemical marker, Postoperative Cognitive Dysfunction
Brief summary
Neuronal damage caused by neuroinflammation in patients undergoing major surgery is the most determinant factor of postoperative cognitive disfunction (POCD). Neuronal damage can be detected through the measurement of biochemical markers of brain damage. The aim of this study was to evaluate neuronal damage and its association with POCD during liver transplantations. After the approval of the ethics committee and patient consents, preoperative and postoperative cognitive functions of 33 patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels. As a result, there was no statistically significant difference between preoperative and postoperative MMTs. However, there was a statistically significant decrease in postoperative GFAP and a statistically significant increase in NSE compared to preoperative values. The decrease in S100β level was statistically insignificant. In conclusion, neuroprotective approaches in the investigator's anesthesia protocol protect patients from brain damage during liver transplantation and prevent the development of POCD, which was indicated by the insignificant change in MMT scores and S100β level and the significant decrease in GFAP. Since the significant increase in NSE levels during liver transplantations was deemed to might have been associated with causes other than neuronal damage, NSE should not be evaluated as a marker of brain damage in these operations.
Interventions
DIAGNOSTIC_TESTMini Mental Test (MMT), S-100 beta, Neuron specific enolase and Glial fibrillary acidic protein
Patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels.
Sponsors
Ege University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Score of 23 or above on the Mini Mental Test (MMT) conducted in the preparation room prior to the operation, * No gastrointestinal bleeding in the last 1 month * No history of neuroactive drug use * Consented for the study.
Exclusion criteria
* Hepatic encephalopathy, * Neurological disorder * Psychiatric disorder,
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Neuron specific enolase (NSE) | Throughout the operation | NSE should not be evaluated as a marker of brain damage in liver transplantations. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| S-100 beta (S100β), and Glial fibrillary acidic protein (GFAP) | Throughout the operation | Neuroprotective approach protects patients from brain damage during liver transplantation and prevent the development of POCD, which was indicated by the insignificant change in MMT scores and S100β level and the significant decrease in GFAP. |
Countries
Turkey (Türkiye)
Outcome results
None listed